Back to top

Image: Bigstock

Vir (VIR) Looks Good: Stock Adds 12.9% in Session

Read MoreHide Full Article

Vir Biotechnology, Inc. (VIR - Free Report) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $16.26 –$60.20 in the past one-month time frame, witnessed a sharp increase yesterday.

The upmove came after the company announced a research collaboration agreement with the National Institutes of Health Vaccine Research Center to develop antibodies against coronaviruses, including SARS-CoV-2.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Vir currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Vir Biotechnology, Inc. Price

Investors interested in the Medical - Biomedical and Genetics industry may consider Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is VIR going up? Or down? Predict to see what others think:Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Regeneron Pharmaceuticals, Inc. (REGN) - free report >>

Vir Biotechnology, Inc. (VIR) - free report >>

Published in